Skip to content
← Full study record

NCT00509249 · MORE INFO

Limitations, agreements, and source contact

Aflibercept in Treating Patients With Myelodysplastic Syndromes · Source last updated 2015-01-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
Study was terminiated after completion of the first stage due to a lack of activity (no hematological responses were observed).
point Of Contact
email
CCCP@coh.org
organization
California Cancer Consortium
phone
626-256-4673
phone Ext
60094
title
DCC Project Administrator
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
limitations And Caveats
description
Study was terminiated after completion of the first stage due to a lack of activity (no hematological responses were observed).
point Of Contact
email
CCCP@coh.org
organization
California Cancer Consortium
phone
626-256-4673
phone Ext
60094
title
DCC Project Administrator

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice